MedTrace Logo

Heparin Induced Thrombocytopenia: Pharmacoeconomics

NCT00456001 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2009-03-02

No results posted yet for this study

Summary

Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study.

Subsequently, we will compare the heparin induced thrombocytopenia rates associated with heparin and low molecular weight heparin usage as well as evaluate the economic and long-term clinical burden of heparin induced thrombocytopenia.

Conditions

  • Heparin Induced Thrombocytopenia (HIT)

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Samuel Z. Goldhaber, MD · Brigham and Women's Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-09-30
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456001 on ClinicalTrials.gov